Download PDF
Horm Metab Res 2004; 36(11/12): 761-765
DOI: 10.1055/s-2004-826160
Review
© Georg Thieme Verlag KG Stuttgart · New York

Circulation and Degradation of GIP and GLP-1

C.  F.  Deacon1
  • 1 Department of Medical Physiology, The Panum Institute, Copenhagen, Denmark
Further Information

Publication History

Received 7 July 2004

Accepted without revision 13 July 2004

Publication Date:
18 January 2005 (online)

Also available at
    Permissions and Reprints

Abstract

The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted from the intestinal K- and L-cells, respectively, but are immediately subject to rapid degradation. GLP-1 is found in two active forms, amidated GLP-1 (7-36) amide and glycine-extended GLP-1 (7-37), while GIP exists as a single 42 amino acid peptide. The aminopeptidase, dipeptidyl peptidase IV (DPP IV), which is found in the endothelium of the local capillary bed within the intestinal wall, is important for the initial inactivation of both peptides, with GLP-1 being particularly readily degraded. DPP IV cleavage generates N-terminally truncated metabolites (GLP-1 (9-36) amide / (9-37) and GIP (3-42)), which are the major circulating forms. Subsequently, the peptides may be degraded by other enzymes and extracted in an organ-specific manner. However, other endogenous metabolites have not yet been identified, possibly because existing assays are unable either to recognize them or to differentiate them from the primary metabolites. Neutral endopeptidase 24.11 has been demonstrated to be able to degrade GLP-1 in vivo, but its relevance in GIP metabolism has not yet been established. Intact GLP-1 and GIP are inactivated during passage across the hepatic bed by DPP IV associated with the hepatocytes, and further degraded by the peripheral tissues, while the kidney is important for the final elimination of the metabolites.

Key words

Glucagon-like peptide-1 - Glucose-dependent insulinotropic polypeptide - Gut hormone - Incretin - Dipeptidyl peptidase IV - Neutral endopeptidase 24.11

References

  • 1 Buchan A M, Polak J M, Capella C, Solcia E, Pearse A G. Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man.  Histochemistry. 1978;  56 37-44
    CrossrefPubMedSearch in Google Scholar
  • 2 Damholt A B, Kofod H, Buchan A M. Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine.  Cell Tissue Res. 1999;  298 287-293
    CrossrefPubMedSearch in Google Scholar
  • 3 Mortensen K, Christensen L L, Holst J J, Ørskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine.  Regul Pept. 2003;  114 189-196
    CrossrefPubMedSearch in Google Scholar
  • 4 Eissele R, Göke R, Willemer S, Harthus H P, Vermeer H, Arnold R, Göke B. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man.  Eur J Clin Invest. 1992;  22 283-291
    CrossrefPubMedSearch in Google Scholar
  • 5 Bell G I, Santerre R F, Mullenbach G T. Hamster preproglucagon contains the sequence of glucagon and two related peptides.  Nature. 1983;  302 716-718
    CrossrefPubMedSearch in Google Scholar
  • 6 Lund P K, Goodman R H, Dee P C, Habener J F. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem.  Proc Natl Acad Sci USA. 1982;  79 345-349
    PubMedSearch in Google Scholar
  • 7 Ørskov C, Rabenhoj L, Wettergren A, Kofod H, Holst J J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans.  Diabetes. 1994;  43 535-539
    PubMedSearch in Google Scholar
  • 8 Mojsov S, Weir G C, Habener J F. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.  J Clin Invest. 1987;  79 616-619
    CrossrefPubMedSearch in Google Scholar
  • 9 Hansen L, Hartmann B, Bisgaard T, Mineo H, Jorgensen P N, Holst J J. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum.  Am J Physiol. 2000;  278 E1010-E1018
    PubMedSearch in Google Scholar
  • 10 Deacon C F, Wamberg S, Bie P, Hughes T E, Holst J J. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.  J Endocrinol. 2002;  172 355-362
    CrossrefPubMedSearch in Google Scholar
  • 11 Ørkov C, Wettergren A, Holst J J. Biological effects and metabolic rates of glucagonlike peptide-1 7 - 36 amide and glucagonlike peptide-1 7 - 37 in healthy subjects are indistinguishable.  Diabetes.. 1993;  42 658-661
    PubMedSearch in Google Scholar
  • 12 Wettergren A, Pridal L, Wojdermann M, Holst J J. Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans.  Regul Pept. 1998;  77 83-87
    CrossrefPubMedSearch in Google Scholar
  • 13 Deacon C F, Johnsen A H, Holst J J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.  J Clin Endocrinol Metab. 1995;  80 952-957
    CrossrefPubMedSearch in Google Scholar
  • 14 Kieffer T J, McIntosh C H, Pederson R A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.  Endocrinology. 1995;  136 3585-3596
    CrossrefPubMedSearch in Google Scholar
  • 15 Pridal L, Deacon C F, Kirk O, Christensen J V, Carr R D, Holst J J. Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36) amide in dogs and is degraded more quickly in vitro by dog plasma.  Eur J Drug Metab Pharmacokinet. 1996;  21 51-59
    PubMedSearch in Google Scholar
  • 16 Knudsen L B, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor.  Eur J Pharmacol. 1996;  318 429-435
    CrossrefPubMedSearch in Google Scholar
  • 17 Pauly R P, Rosche F, Wermann M, McIntosh C H, Pederson R A, Demuth H U. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach.  J Biol Chem. 1996;  271 23222-23229
    CrossrefPubMedSearch in Google Scholar
  • 18 Takeda J, Seino Y, Tanaka K, Fukumoto H, Kayano T, Takahashi H, Mitani T, Kurono M, Suzuki T, Tobe T, Imura H. Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor.  Proc Natl Acad Sci USA. 1987;  84 7005-7008
    PubMedSearch in Google Scholar
  • 19 Tseng C C, Jarboe L A, Landau S B, Williams E K, Wolfe M M. Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat.  Proc Natl Acad Sci USA. 1993;  90 1992-1996
    PubMedSearch in Google Scholar
  • 20 Burhol P G, Jorde R, Waldum H L. Radioimmunoassay of plasma gastric inhibitory polypeptide (GIP), release of GIP after a test meal and duodenal infusion of bile, and immunoreactive plasma GIP components in man.  Digestion. 1980;  20 336-345
    PubMedSearch in Google Scholar
  • 21 Krarup T, Holst J J. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera.  Regul Pept. 1984;  9 35-46
    CrossrefPubMedSearch in Google Scholar
  • 22 Krarup T, Holst J J, Larsen K L. Responses and molecular heterogeneity of IR-GIP after intraduodenal glucose and fat.  Am J Physiol.. 1985;  249 E195-E200
    PubMedSearch in Google Scholar
  • 23 Otte S C, Mutt V, McIntosh C HS, Brown J C. Purification and amino acid composition of an 8000 dalton immunoreactive form of GIP.  Dig Dis Sci. 1984;  29 (Suppl) 63S (abstract)
    PubMedSearch in Google Scholar
  • 24 Jörnvall H, Carlquist M, Kwauk S, Otte S C, McIntosh C H, Brown J C, Mutt V. Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP).  FEBS Lett. 1981;  123 205-210
    CrossrefPubMedSearch in Google Scholar
  • 25 Deacon C F, Nauck M A, Meier J, Hucking K, Holst J J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.  J Clin Endocrinol Metab. 2000;  85 3575-3581
    CrossrefPubMedSearch in Google Scholar
  • 26 Nauck M A, Kleine N, Ørskov C, Holst J J, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.  Diabetologia. 1993;  36 741-744
    CrossrefPubMedSearch in Google Scholar
  • 27 Gutniak M K, Linde B, Holst J J, Efendic S. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.  Diabetes Care. 1994;  17 1039-1044
    CrossrefPubMedSearch in Google Scholar
  • 28 Nauck M A, Wollschlager D, Werner J, Holst J J, Ørskov C, Creutzfeldt W, Willms B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.  Diabetologia. 1996;  39 1546-1553
    CrossrefPubMedSearch in Google Scholar
  • 29 Buckley D I, Lundquist P. Analysis of the degradation of insulinotropin [GLP-1 (7-37)] in human plasma and production of degradation resistant analogs.  Reg Pept. 1992;  40 117 (abstract)
    PubMedSearch in Google Scholar
  • 30 Mentlein R, Gallwitz B, Schmidt W E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7 - 36) amide, peptide histidine methionine and is responsible for their degradation in human serum.  Eur J Biochem. 1993;  214 829-835
    CrossrefPubMedSearch in Google Scholar
  • 31 Adelhorst K, Hedegaard B B, Knudsen L B, Kirk O. Structure-activity studies of glucagon-like peptide-1.  J Biol Chem. 1994;  269 6275-6278
    PubMedSearch in Google Scholar
  • 32 Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides.  Regul Pept. 1999;  85 9-24
    CrossrefPubMedSearch in Google Scholar
  • 33 Deacon C F, Nauck M A, Toft-Nielsen M, Pridal L, Willms B, Holst J J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects.  Diabetes. 1995;  44 1126-1131
    CrossrefPubMedSearch in Google Scholar
  • 34 Deacon C F, Wamberg S, Bie P, Hughes T E, Holst J J. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.  J Endocrinol. 2002;  172 355-362
    CrossrefPubMedSearch in Google Scholar
  • 35 Vilsboll T, Agerso H, Krarup T, Holst J J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.  J Clin Endocrinol Metab. 2003;  88 220-224
    CrossrefPubMedSearch in Google Scholar
  • 36 Meier J J, Nauck M A, Kranz D, Holst J J, Deacon C F, Gaeckler D, Schmidt W E, Gallwitz B. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.  Diabetes. 2004;  53 654-662
    CrossrefPubMedSearch in Google Scholar
  • 37 Hansen L, Deacon C F, Ørskov C, Holst J J. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.  Endocrinology. 1999;  140 5356-5363
    CrossrefPubMedSearch in Google Scholar
  • 38 Marguet D, Baggio L, Kobayashi T, Bernard A M, Pierres M, Nielsen P F, Ribel U, Watanabe T, Drucker D J, Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.  Proc Natl Acad Sci USA. 2000;  97 6874-6879
    CrossrefPubMedSearch in Google Scholar
  • 39 Deacon C F, Hughes T E, Holst J J. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.  Diabetes. 1998;  47 764-769
    CrossrefPubMedSearch in Google Scholar
  • 40 Deacon C F, Danielsen P, Klarskov L, Olesen M, Holst J J. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs.  Diabetes. 2001;  50 1588-1597
    PubMedSearch in Google Scholar
  • 41 Balkan B, Kwasnik L, Miserendino R, Holst J J, Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.  Diabetologia. 1999;  42 1324-1331
    CrossrefPubMedSearch in Google Scholar
  • 42 Pedersen R A, White H A, Schlenzig D, Pauly R P, McIntosh C H, Demuth H U. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide.  Diabetes. 1998;  47 1253-1258
    PubMedSearch in Google Scholar
  • 43 Ahrén B, Holst J J, Marensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.  Eur J Pharmacol. 2000;  404 239-245
    CrossrefPubMedSearch in Google Scholar
  • 44 Pospisilik J A, Stafford S G, Demuth H U, Brownsey R, Parkhouse W, Finegood D T, McIntosh C H, Pederson R A. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats.  Diabetes. 2002;  51 943-950
    PubMedSearch in Google Scholar
  • 45 Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson P A, Sandqvist M, Bavenholm P, Efendic S, Eriksson J W, Dickinson S, Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.  Diabetes Care. 2002;  25 869-875
    PubMedSearch in Google Scholar
  • 46 Ahrén B, Landin-Olsson M, Jansson P A, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.  J Clin Endocrinol Metab. 2004;  89 2078-2084
    CrossrefPubMedSearch in Google Scholar
  • 47 Hupe-Sodmann K, McGregor G P, Bridenbaugh R, Goke R, Goke B, Thole H, Zimmermann B, Voigt K. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides.  Regul Pept. 1995;  58 149-156
    CrossrefPubMedSearch in Google Scholar
  • 48 Hupe-Sodmann K, Goke R, Goke B, Thole H H, Zimmermann B, Voigt K, McGregor G P. Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells.  Peptides. 1997;  18 625-632
    CrossrefPubMedSearch in Google Scholar
  • 49 Plamboeck A, Holst J J, Carr R D, Deacon C F. The degradation of glucagon-like peptide-1 involves both dipeptidyl peptidase IV and neutral endopeptidase 24.11 in vivo.  Regul Pept. 2004;  122 6 (Abstract)
    PubMedSearch in Google Scholar
  • 50 O’Dorisio T M, Sirinek K R, Mazzaferri E L, Cataland S. Renal effects on serum gastric inhibitory polypeptide (GIP).  Metabolism. 1977;  26 651-656
    CrossrefPubMedSearch in Google Scholar
  • 51 Sirinek K R, O’Dorisio T M, Gaskill H V, Levine B A. Chronic renal failure: effect of hemodialysis on gastrointestinal hormones.  Am J Surg. 1984;  148 732-735
    CrossrefPubMedSearch in Google Scholar
  • 52 Ørskov C, Andreasen J, Holst J J. All products of proglucagon are elevated in plasma from uremic patients.  J Clin Endocrinol Metab. 1992;  74 379-384
    CrossrefPubMedSearch in Google Scholar
  • 53 Jorde R, Burhol P G, Gunnes P, Schulz T B. Removal of IR-GIP by the kidneys in man, and the effect of acute nephrectomy on plasma GIP in rats.  Scand J Gastroenterol. 1981;  16 469-471
    PubMedSearch in Google Scholar
  • 54 Ruiz-Grande C, Alarcon C, Alcantara A, Castilla C, Lopez N ovoa, Villanueva-Penacarrillo M L, Valverde I. Renal catabolism of truncated glucagon-like peptide 1.  Horm Metab Res. 1993;  25 612-616
    PubMedSearch in Google Scholar
  • 55 Deacon C F, Pridal L, Klarskov L, Olesen M, Holst J J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig.  Am J Physiol. 1996;  271 E458-E464
    PubMedSearch in Google Scholar
  • 56 Simonsen L. A comparison of the metabolism of GLP-1 and exendin-4 - focus on the role of the kidney. Masters thesis, Faculty of Health Sciences, University of Copenhagen 2004
    Search in Google Scholar
  • 57 Carone F A, Peterson D R, Flouret G. Renal tubular processing of small peptide hormones.  J Lab Clin Med. 1982;  100 1-14
    PubMedSearch in Google Scholar
  • 58 Emmanouel D S, Jaspan J B, Rubenstein A H, Huen A H, Fink E, Katz A I. Glucagon metabolism in the rat.  J Clin Invest. 1978;  62 6-13
    PubMedSearch in Google Scholar
  • 59 Hanks J B, Andersen D K, Wise J E, Putnam W S, Meyers W C, Jones R S. The hepatic extraction of gastric inhibitory polypeptide and insulin.  Endocrinology. 1984;  115 1011-1018
    PubMedSearch in Google Scholar
  • 60 Chap Z, O’Dorisio T M, Cataland S, Field J B. Absence of hepatic extraction of gastric inhibitory polypeptide in conscious dogs.  Dig Dis Sci. 1987;  32 280-284
    CrossrefPubMedSearch in Google Scholar
  • 61 Elovson J. Biogenesis of plasma membrane glycoproteins. Purification and properties of two rat liver plasma membrane glycoproteins.  J Biol Chem. 1980;  255 5807-5815
    PubMedSearch in Google Scholar

Dr. C. F. Deacon

Department of Medical Physiology, Panum Institute

Blegdamsvej 3 · 2200 Copenhagen N · Denmark

Phone: +45 3532 7523

Fax: +45 3532 7537

Email: deacon@mfi.ku.dk